SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001193125-21-328083
Filing Date
2021-11-12
Accepted
2021-11-12 16:10:04
Documents
16
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q/A d254048d10qa.htm   iXBRL 10-Q/A 34456
2 EX-31.1 d254048dex311.htm EX-31.1 10988
3 EX-31.2 d254048dex312.htm EX-31.2 10976
  Complete submission text file 0001193125-21-328083.txt   221956

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA alna-20210331.xsd EX-101.SCH 4686
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE alna-20210331_cal.xml EX-101.CAL 684
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE alna-20210331_def.xml EX-101.DEF 1689
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE alna-20210331_lab.xml EX-101.LAB 18535
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alna-20210331_pre.xml EX-101.PRE 14785
9 EXTRACTED XBRL INSTANCE DOCUMENT d254048d10qa_htm.xml XML 5783
Mailing Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462
Business Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462 617-467-4577
Allena Pharmaceuticals, Inc. (Filer) CIK: 0001624658 (see all company filings)

IRS No.: 452729920 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-38268 | Film No.: 211403527
SIC: 2836 Biological Products, (No Diagnostic Substances)